Minoryx and Neuraxpharm complete enrolment in leriglitazone pivot...

Mataró, Barcelona, Spain, and Düsseldorf, Germany, 09 September 2026 - Minoryx Therapeutics and Neuraxpharm Group (Neuraxpharm), announce that the last patient has been enrolled in the global Phase 3 clinical trial (CALYX) evaluating leriglitazone (NEZGLYAL®) in adult male patients with cerebral Adrenoleukodystrophy (cALD), an orphan neurodegenerative disease with no pharmacological therapeutic options. In Europe, leriglitazone has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of boys aged 2-12 with cALD and non-gadolinium enhancing lesions. Approval under exceptional circumstances from the European Commission (EC) is expected later this month and Neuraxpharm, a leading CNS specialist company and Minoryx's strategic partner in Europe, is preparing for the commercial launch.

Read More